Communiqués Chugai Pharmaceutical Co., Ltd.

Actions

4519

JP3519400000

Produits pharmaceutiques

Temps Différé Japan Exchange Autres places de cotation 08:30:00 04/08/2026			Varia. 5j.	Varia. 1 janv.
6 680,00 ^JPY	-0,10%		-2,45%	-18,96%

31/07	Chugai Pharmaceutical sollicite une extension d'indication pour l'Enspryng dans la prévention des rechutes de la maladie associée aux anticorps anti-MOG au Japon	CI
24/07	Transcript : Chugai Pharmaceutical Co., Ltd., Q2 2026 Earnings Call, Jul 24, 2026

Communiqués

30/07	Chugai Pharmaceutical Co., Ltd. - Support for Areas Affected by the 2026 Kumamoto Prefecture Earthquake	AQ
27/07	Chugai Announces 2026 2nd Quarter Results	AQ
22/06	Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy	AQ
26/05	Chugai Receives The Imperial Invention Prize, the Highest Honor of the FY2026 National Commendation for Invention, Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research	AQ
18/05	Chugai Pharmaceutical : Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients	PU
18/05	Chugai Pharmaceutical : Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors	PU
27/04	Chugai Pharmaceutical : Script (including Q&A)	PU
27/04	Chugai Pharmaceutical : Evaluation Results of Effectiveness of the Board of Directors (Apr. 27, 2026)	PU
24/04	Chugai Pharmaceutical : Supplementary Materials Supplementary Materials	PU
24/04	Chugai Pharmaceutical : Q1 Results (Jan-Mar 2026)	PU
09/04	Chugai Pharmaceutical : Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody)	PU
27/03	Chugai Pharmaceutical : Voting Results (Extraordinary Report) of the 115th Annual General Meeting of Shareholders	PU
26/03	Chugai Pharmaceutical : Notice of Resolution of the 115th Annual General Meeting of Shareholders	PU
24/03	Chugai Pharmaceutical - Notice Regarding Discontinuation of Development of GYM329 in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy	AQ
23/03	Chugai Pharmaceutical : Obtains Regulatory Approval for Lunsumio and Polivy Combination Therapy for Additional Indication of Relapsed or Refractory Large B-cell Lymphoma	PU
23/03	Chugai Pharmaceutical : Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD)	PU
19/03	Chugai Pharmaceutical : Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan	PU
19/03	Chugai Pharmaceutical : Selected as a “Nadeshiko Brand” for FY2025	PU
11/03	Chugai Pharmaceutical Co., Ltd. - Roche's Announcement Regarding giredestrant	AQ
24/02	Chugai Pharmaceutical : Notice of Convocation of the 115th Annual General Meeting of Shareholders	PU
24/02	Chugai Pharmaceutical : Business Report of the 115th Annual General Meeting of Shareholders	PU
20/02	Chugai Pharmaceutical : Launches “ELEVIDYS” as Japan’s First Regenerative Medical Product for Duchenne Muscular Dystrophy	PU
19/02	Chugai Pharmaceutical : Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Autoimmune Hemolytic Anemia	PU
09/02	Chugai Pharmaceutical : NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period	PU
30/01	Chugai Announces 2025 Full Year Results and Forecasts for 2026	AQ